Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design
This trial will provide novel data on myocardial effects of SGLT2i in dialysis recipients. Results from this study may provide evidence to support SGLT2i use in ESKD.
Authors
- Isabella Bonilha (ORCID: https://orcid.org/0000-0002-5581-5763)
- Daniel Campos Jesus (ORCID: https://orcid.org/0000-0003-0254-9972)
- Barbara Assato (ORCID: https://orcid.org/0000-0003-0565-0216)
- Wilson Nadruz (ORCID: https://orcid.org/0000-0002-0003-5102)
- Alessandra M. Campos‐Staffico (ORCID: https://orcid.org/0000-0003-4172-7524)
- Cinthia Esbrile Moraes Carbonara (ORCID: https://orcid.org/0000-0003-2786-9200)
- Mauro Alexandre Páscoa (ORCID: https://orcid.org/0000-0003-4685-6990)
- Kélcia Rosana da Silva Quadros (ORCID: https://orcid.org/0000-0003-4510-4674)
- Sheila T. K. Medorima
- Gil Guerra‐Júnior (ORCID: https://orcid.org/0000-0002-2991-7678)
- Andrei C. Spósito (ORCID: https://orcid.org/0000-0001-7127-2052)
- Rodrigo Bueno de Oliveira (ORCID: https://orcid.org/0000-0002-8273-6200)
- Joaquim Barreto
- Marília da Glória Martins
Institutions
- Creighton University (US)
- Universidade Estadual de Campinas (UNICAMP) (BR)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1080/14740338.2024.2412228
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07